Ronald Berger, MD
Cardiovascular Disease · Bannockburn, ILNPI 1730109851
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $129,225 of the $150,078 with a category attached, or 86.1%. Irhythm Technologies, Inc. accounts for 86.1% of it on its own, with 34 other manufacturers making up the rest. Reporting peaked in 2023 at $43,260 and has fallen 95.1% since, to $2,137 in 2025. Among cardiovascular disease clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 517 payments — averaging $290.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Irhythm Technologies, Inc.$129K
- Boehringer Ingelheim$7K
- Novo Nordisk$2K
- Johnson & Johnson$2K
- Novartis$2K
- Medtronic$1K
- plus $6K from 29 others
What the payments were for
- Consulting fees$129,22586%
- Speaking & faculty fees$5,4604%
- Food & beverage$15,30810%
- Education$850%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Irhythm Technologies, Inc. | 42 | $129,255 |
| Boehringer Ingelheim | 42 | $6,829 |
| Novo Nordisk | 55 | $2,401 |
| Johnson & Johnson | 55 | $1,998 |
| Novartis | 75 | $1,832 |
| Medtronic(2 entities) | 30 | $1,495 |
| Amgen | 28 | $1,053 |
| AstraZeneca | 40 | $875 |
| E.r. Squibb & Sons, L.L.C. | 45 | $847 |
| Boston Scientific | 25 | $574 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $438 |
| Pfizer | 17 | $414 |
| Abbott | 10 | $285 |
| Sanofi-aventis U.S. LLC | 2 | $207 |
| Edwards Lifesciences | 2 | $202 |
| Impulse Dynamics (USA) Inc. | 1 | $176 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $129 |
| Cvrx, Inc. | 2 | $116 |
| Actelion Pharmaceuticals US, Inc. | 3 | $114 |
| Biosense Webster, Inc. | 3 | $111 |
| Janssen Scientific Affairs, LLC | 1 | $103 |
| Merck | 4 | $99 |
| Abiomed | 3 | $92 |
| Scpharmaceuticals Inc. | 3 | $59 |
| Lexicon Pharmaceuticals, Inc. | 3 | $55 |
| Alnylam Pharmaceuticals Inc. | 2 | $52 |
| Philips North America LLC | 1 | $51 |
| Bayer | 2 | $48 |
| Esperion Therapeutics, Inc. | 2 | $43 |
| Davol Inc. | 1 | $26 |
| Coloplast | 1 | $25 |
| Ionis Pharmaceuticals, Inc. | 1 | $24 |
| Chiesi USA, Inc. | 1 | $20 |
| Lantheus Medical Imaging, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZIO XT Patch$115,725
- ZIO Patch$13,500
- PRADAXA$5,585
- XARELTO$872
- Ozempic$715
- Repatha$626
- LEQVIO$510
- LINQ II$486
- OPTIMIZER$352
- JARDIANCE$347
- LifeVest$329
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$162
- Reveal XT$145
- MULTAQ$127
- Corlanor$125
- AURORA EV-ICD MRI SURESCAN$121
- Wegovy$120
- VYNDAQEL$118
- FARXIGA$117
- SelectSecure$117
How this compares
$150,078 in reported general payments places this provider in the 95th percentile of 932 cardiovascular disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 472 | $637,010 |
| XareltoRivaroxaban | 235 | $317,448 |
| EntrestoSacubitril/Valsartan | 57 | $67,406 |
| Repatha SureclickEvolocumab | 78 | $54,839 |
| MultaqDronedarone Hcl | 23 | $44,140 |
| OzempicSemaglutide | 21 | $28,604 |
| FarxigaDapagliflozin Propanediol | 15 | $26,181 |
| JardianceEmpagliflozin | 20 | $23,259 |
| VascepaIcosapent Ethyl | 19 | $13,765 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 24 | $11,663 |
| Atorvastatin Calcium | 955 | $11,037 |
| Nebivolol Hcl | 117 | $9,946 |
| Metoprolol Succinate | 489 | $8,945 |
| Ezetimibe | 254 | $7,445 |
| Dofetilide | 11 | $6,976 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $414 | $637,010472 claims |
| Johnson & JohnsonXarelto | $1,998 | $317,448235 claims |
| NovartisEntresto | $1,832 | $67,40657 claims |
| Sanofi-aventis U.S. LLCMultaq | $207 | $44,14023 claims |
| Novo NordiskOzempic | $2,401 | $28,60421 claims |
| AstraZenecaFarxiga | $875 | $26,18115 claims |
| Boehringer IngelheimJardiance | $6,829 | $23,25920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 932 cardiovascular disease providers in Illinois.
Other cardiovascular disease in Bannockburn
- Jay AlexanderBannockburn$744K
- David DavidsonBannockburn$265K
- Sandeep NathanChicago$892K
- Alan BrownNaperville$858K
- Azmey MatariehElgin$762K
- Niraj VarmaMaywood$522K
- Boaz AvitallChicago$366K
- Akhil NarangChicago$363K
- Mark RabbatMaywood$363K
- Michael DavidsonChicago$317K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.